Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Patients with CDI often have persistent infections or develop new infections during the course of CDI treatment and are often administered concomitant antibiotics. Although clinically necessary the use of concomitant antibiotics has a deleterious effect on outcomes of cure, recurrence and global cure. Compared to vancomycin therapy, fidaxomicin blunts these negative effects by significantly lowering recurrences and increasing global cure of patients," said Pedro Lichtinger, Optimer's President and Chief Executive Officer.  "The additional data presented suggest fidaxomicin has the potential to become the product of choice for CDI, if approved."

Kathleen M. Mullane, D.O., Pharm. D., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented combined data from Optimer's two Phase 3 trials indicating that the use of concomitant antibiotics is a significant risk factor for a negative CDI treatment outcome.  Many patients with CDI have persistent infections or develop new infections during the course of CDI treatment making concomitant antibiotics clinically necessary and common.  Overall, 34% of subjects received antibiotics in addition to fidaxomicin a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... On Friday, December 19, 2014, ... Omnibus and Continuing Resolution Appropriations Act of 2015, ... condition eligible to receive funding through the Congressionally ... Department of Defense (DoD). The Hydrocephalus Association (HA), ... Hill, is celebrating this victory for the over ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... June 25, 2009 Veritide Ltd., a developer of ... new independent data to be presented at the Biodetection ... Ceeker (pronounced "seeker") portable bacterial detection device in discriminating ... data show that in over two weeks of testing ...
... SAN MARINO, Calif., July 8 Biotechnology company Viral ... financial disclosures through the OTCIQ.com portal, that provides information ... website. The website is an online point of ... Sheets" over-the-counter market. Investors can access and download all ...
... , SAN FRANCISCO, July 8 Nile Therapeutics, Inc. (Nasdaq: ... of novel therapeutics for heart failure patients, today announced that ... private placement securities of the Company for aggregate gross proceeds ... broker dealer, acted as the exclusive placement agent for the ...
Cached Biology Technology:Novel handheld device detects anthrax with outstanding accuracy and reliability 2Novel handheld device detects anthrax with outstanding accuracy and reliability 3Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website 2Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website 3Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 2Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 3Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement 4
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... may help us breed and select plants that would better ... The paper, which offers the first example of a gene ... the July 12 issue of Current Biology. "It's very exciting," ... Campbell. "This is a gene that helps regulate carbon dioxide ...
... to cause a dangerous nerve condition called neuropathy that ... led by Baylor College of Medicine in Houston. , ... Medical Science in Japan, and the University of Chicago ... Academy of Sciences. , The finding not only provides ...
... vast ecosystem beneath the collapsed Larsen Ice Shelf will ... floating ice shelves and further probe the origins of ... after a recent underwater video study examining a deep ... sudden Larsen B shelf collapse in 2002. , "This ...
Cached Biology News:Genetic discovery could lead to drought-resistant plants 2Malfunctioning bone marrow cells sabotage nerve cells in diabetes 2Discovering an ecosystem beneath a collapsed Antarctic ice shelf 2